Log in for full access to this activity, if you are registered.

Registration Options

Activity Dates: 07/01/2014 - 07/01/2017

This course is closed. Please look for other available products in CPNP University.

Target Audience

This application-level activity is designed for pharmacists and other healthcare professionals with moderate experience in psychiatric pharmacotherapy. This learning activity would be valuable for residents/fellows, new psychiatric health care professionals, primary care physicians, general practitioners, and general ARNP/PAs.

Session Summary

This course is designed to provide participants with moderate experience a review of evidenced-based, second- and third-line strategies for the treatment of obsessive-compulsive disorder. The goal is for participants to formulate an effective and safe drug therapy plan that can be implemented in a patient with comorbid disease states/drug related problems who has failed first-line therapy. Differentiation between treatment resistance and non-treatment resistance in patients with obsessive-compulsive disorder will also be emphasized. The course will involve review of a recommended reading(s) and analysis of a patient case study with application to an examination. At the conclusion of the course, an evidence-based key will be provided for the case.

Course Requirements

You will proceed through the following steps to satisfactorily complete this course:

  • Complete the pre-test before starting the activity. (login first)
  • Review the full content of the activity and reflect upon its teachings.
  • Complete the post-test at the end of the activity no later than the closing activity date. (login first)
  • Complete the evaluation at the end of the activity. (login first)
  • If necessary, complete the post-test retest no later than the closing activity date. (login first)
  • Receive a passing grade (70%).
  • Provide the necessary details in your profile to ensure correct reporting by CPNP to CPE Monitor. (login first)

The course consists of review of a recommended reading(s) and completion of a patient case study. At the conclusion of the course, an evidence-based key will be provided for the case. If the recommended reading is a CPNP product, it is provided. If not, it is the responsibility of the participant to locate the reading.

Faculty Information and Disclosures

Charles F. Caley, PharmD, BCPP

View biographical information and disclosures

Learning Objectives

  1. Apply evidenced-based pharmacotherapeutic strategies to a patient who has failed first-line therapy for Obsessive-Compulsive Disorder (OCD).
  2. Tailor individualized treatment plans for patients with OCD and co-morbid medical disease states and drug related problems to improve treatment outcomes.
  3. Identify clinician/patient-rated scales for use in the management of patients with OCD.
  4. Differentiate between treatment resistance and non-treatment resistance as it applies to patients with OCD and identify when it is appropriate to refer for management by a psychiatry specialist.

Continuing Education Credit and Disclosures

Activity Dates: 07/01/2014 - 07/01/2017
ACPE Contact Hours: 2.0
ACPE Number: 0284-0000-14-068-H01-P (Application)
Nursing Credit Reminder: Note that ACPE credit is accepted for certification renewal.

ACPEThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This self-study course provides 2.0 contact hours (0.2 CEUs) of application-based continuing education credit. The ACPE universal program number assigned to this course is 0284-0000-14-068-H01-P (2.0 contact hours).

This educational activity does not contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA).

Grant Support

This activity is sponsored by the College of Psychiatric and Neurologic Pharmacists (CPNP) and supported through educational grants from Eli Lilly, Merck, Otsuka America Pharmaceutical Inc., and Sunovion Pharmaceuticals Inc.